FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034819975> ?p ?o ?g. }

• W3034819975 endingPage "1143" @default.
• W3034819975 startingPage "1133" @default.
• W3034819975 abstract "Rationale: There is uncertainty on the optimal first-line therapy for symptomatic chronic obstructive pulmonary disease (COPD). Long-acting β2-receptor agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) have long been mainstays of treatment, though it is still not clear if dual therapy with LABA/LAMA is superior to monotherapy for symptomatic COPD.Objectives: To clarify the evidence landscape, we conducted a systematic review to answer the following question: in patients with COPD who complain of dyspnea and/or exercise intolerance, is LABA/LAMA combination therapy more effective and equally safe compared with LABA or LAMA monotherapy?Methods: A search of Medline, EMBASE, and the Cochrane Library databases was conducted by a medical librarian for randomized controlled trials enrolling patients with COPD who complain of dyspnea and/or exercise intolerance that compare LABA/LAMA combination therapy to LABA or LAMA monotherapy. A systematic approach was used to screen, abstract, and critically appraise the emerging study evidence. The Grading of Recommendations Assessment, Development, and Evaluation method was applied to rate the certainty and quality of the evidence.Results: A total of 24 studies were eligible for inclusion (n = 45,441). Pairwise random-effects meta-analysis revealed reductions in hospital admissions (11% reduction; P < 0.01) and acute exacerbations of COPD (20% reduction; P < 0.002), all in favor of LABA/LAMA dual therapy. Although there is reduced dyspnea (0.10 standardized mean difference; P < 0.001) and improved health-related quality of life (−0.13 standardized mean difference; P < 0.001), both values did not meet a clinical meaningful difference threshold. LABA/LAMA combination therapy showed no difference in treatment-emergent adverse effects (risk ratio, 0.99; P = 0.34) when compared with either LAMA or LABA monotherapy.Conclusions: Based on the reviewed evidence, in patients with symptomatic COPD who complain of dyspnea and/or exercise intolerance, dual LABA/LAMA therapy is superior to either LABA or LAMA monotherapy based on the reduced risk of exacerbations and hospitalizations." @default.
• W3034819975 created "2020-06-19" @default.
• W3034819975 creator A5020157030 @default.
• W3034819975 creator A5057492589 @default.
• W3034819975 creator A5060850749 @default.
• W3034819975 creator A5067232021 @default.
• W3034819975 creator A5072981488 @default.
• W3034819975 creator A5073082660 @default.
• W3034819975 date "2020-09-01" @default.
• W3034819975 modified "2023-10-16" @default.
• W3034819975 title "Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline" @default.
• W3034819975 cites W1950043623 @default.
• W3034819975 cites W1973217968 @default.
• W3034819975 cites W1977733462 @default.
• W3034819975 cites W1980789906 @default.
• W3034819975 cites W1991296122 @default.
• W3034819975 cites W2006528231 @default.
• W3034819975 cites W2010149513 @default.
• W3034819975 cites W2026247098 @default.
• W3034819975 cites W2026585673 @default.
• W3034819975 cites W2039237831 @default.
• W3034819975 cites W2050325691 @default.
• W3034819975 cites W2056040906 @default.
• W3034819975 cites W2060873423 @default.
• W3034819975 cites W2075195662 @default.
• W3034819975 cites W2078552229 @default.
• W3034819975 cites W2086342579 @default.
• W3034819975 cites W2098923148 @default.
• W3034819975 cites W2104636056 @default.
• W3034819975 cites W2104675861 @default.
• W3034819975 cites W2105234929 @default.
• W3034819975 cites W2107328434 @default.
• W3034819975 cites W2111374619 @default.
• W3034819975 cites W2112089312 @default.
• W3034819975 cites W2123850585 @default.
• W3034819975 cites W2128278745 @default.
• W3034819975 cites W2128643475 @default.
• W3034819975 cites W2142449488 @default.
• W3034819975 cites W2165909321 @default.
• W3034819975 cites W2167795093 @default.
• W3034819975 cites W2233753101 @default.
• W3034819975 cites W2284223599 @default.
• W3034819975 cites W2327678559 @default.
• W3034819975 cites W2345974479 @default.
• W3034819975 cites W2346277111 @default.
• W3034819975 cites W2558903543 @default.
• W3034819975 cites W2588781854 @default.
• W3034819975 cites W2591678263 @default.
• W3034819975 cites W2593670800 @default.
• W3034819975 cites W2794699839 @default.
• W3034819975 cites W2818100279 @default.
• W3034819975 cites W2907720513 @default.
• W3034819975 cites W2920797638 @default.
• W3034819975 cites W2940473654 @default.
• W3034819975 cites W2960506719 @default.
• W3034819975 cites W3016201212 @default.
• W3034819975 doi "https://doi.org/10.1513/annalsats.201912-915oc" @default.
• W3034819975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32530702" @default.
• W3034819975 hasPublicationYear "2020" @default.
• W3034819975 type Work @default.
• W3034819975 sameAs 3034819975 @default.
• W3034819975 citedByCount "23" @default.
• W3034819975 countsByYear W30348199752021 @default.
• W3034819975 countsByYear W30348199752022 @default.
• W3034819975 countsByYear W30348199752023 @default.
• W3034819975 crossrefType "journal-article" @default.
• W3034819975 hasAuthorship W3034819975A5020157030 @default.
• W3034819975 hasAuthorship W3034819975A5057492589 @default.
• W3034819975 hasAuthorship W3034819975A5060850749 @default.
• W3034819975 hasAuthorship W3034819975A5067232021 @default.
• W3034819975 hasAuthorship W3034819975A5072981488 @default.
• W3034819975 hasAuthorship W3034819975A5073082660 @default.
• W3034819975 hasConcept C126322002 @default.
• W3034819975 hasConcept C142724271 @default.
• W3034819975 hasConcept C159110408 @default.
• W3034819975 hasConcept C168563851 @default.
• W3034819975 hasConcept C17744445 @default.
• W3034819975 hasConcept C177713679 @default.
• W3034819975 hasConcept C1862650 @default.
• W3034819975 hasConcept C189708586 @default.
• W3034819975 hasConcept C199539241 @default.
• W3034819975 hasConcept C2776478404 @default.
• W3034819975 hasConcept C2776780178 @default.
• W3034819975 hasConcept C2779473830 @default.
• W3034819975 hasConcept C2779951463 @default.
• W3034819975 hasConcept C2780182762 @default.
• W3034819975 hasConcept C2780911369 @default.
• W3034819975 hasConcept C71924100 @default.
• W3034819975 hasConcept C95190672 @default.
• W3034819975 hasConceptScore W3034819975C126322002 @default.
• W3034819975 hasConceptScore W3034819975C142724271 @default.
• W3034819975 hasConceptScore W3034819975C159110408 @default.
• W3034819975 hasConceptScore W3034819975C168563851 @default.
• W3034819975 hasConceptScore W3034819975C17744445 @default.
• W3034819975 hasConceptScore W3034819975C177713679 @default.
• W3034819975 hasConceptScore W3034819975C1862650 @default.
• W3034819975 hasConceptScore W3034819975C189708586 @default.
• W3034819975 hasConceptScore W3034819975C199539241 @default.

• next